Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Special Report
PBAC reveals giant November agenda
As anticipated, the November 2016 PBAC agenda is huge with 36 major submissions and 26 minor but comparatively few on the parallel processing track.
Approvals Action
Apotex sets sights on $146m Novartis drug
Apotex has registered two new brands for one of Novartis' biggest selling products as patent expiry looms.
PBAC Outcomes
PBAC in major denial mode
The PBAC either rejected or deferred 16 major submissions and resubmissions at its July meeting with another three parallel submissions held off because TGA data was insufficient; only seven majors were recommended for listing.
Pipeline Monitor
Gilead wins speedy review for HIV hope
Gilead has filed its latest drug combo in the US with hopes of maintaining HIV sales as hep C blockbusters fall back.